Clinical Trial Update: Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating Imprime PGG with Alemtuzumab and Rituximab in high-risk chronic lymphocytic leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Imprime PGG
• Rituximab (rituximab)

Snippet

Sponsor: Mayo Clinic | Conditions: B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-06-23